CRDF today
$0.73-$0.00 (-0.16%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourDescending Triangle
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $1.50
Key levels
Resistance$0.87
Resistance$0.75
Latest news & SEC filings
SEC FilingCardiff Oncology, Inc. filed a report on a major company event (Form 8-K)
EarningsCardiff Oncology Posts Q3 2026 Results, Gives Business Update
EarningsCardiff Oncology posts smaller quarterly loss than expected, revenue tops estimate
All CRDF news →About Cardiff Oncology
Cardiff Oncology is a drug development firm focused on treating tumors through inhibition of the PLK1 protein. Its main experimental medicine, onvansertib, is taken by mouth and is being studied alongside existing chemotherapy regimens in several cancer types, including colorectal, pancreatic, lung and breast tumors, plus a blood cancer. The company is based in the United States and runs its trials with partners and academic researchers.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
Cardiff Oncology, Inc. (CRDF)
What Is the Price Target for CRDF?
SEPT Low Target
$2.00
SEPT Mid Target
$2.00
SEPT High Target
$2.00
Analyst Consensus
$2.00
Is CRDF a Buy or Sell Right Now?
Thesis
- •Revenue growing -13.2% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRDF.
Start Free Trial →Is CRDF Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.75
23
Moat Score
NONE
2/9
Piotroski Score
-9.6
Altman Z-Score
What Is Smart Money Doing with CRDF?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CRDF Growth Story
Revenue YoY
-13.2%
3yr Revenue CAGR
15.4%
EPS Growth YoY
27.37%
FCF Growth YoY
-0.5%
Revenue Trend
STRONG
Dark Pool Trades for CRDF
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CRDF, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:05:56 | $0.72 | 1,025 | $$738 | SELL |
| 18:01:05 | $0.72 | 1,000 | $$720 | SELL |
| 17:53:40 | $0.72 | 9,000 | $$6K | BUY |
| 17:52:01 | $0.72 | 9,000 | $$6K | BUY |
| 17:52:01 | $0.72 | 1,000 | $$718 | BUY |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CRDF
PREVIEWSEPT Investing provides real-time options flow tracking for CRDF, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1 | Jan 15 | 63 | $$500 | 100 | BLOCK |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Cardiff Oncology, Inc. (CRDF) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CRDF — frequently asked questions
What is CRDF stock price today?
Cardiff Oncology, Inc. (CRDF) is at $0.73, down 0.16% (-$0.00) at the Nov 13, 2026 close.
Why is CRDF stock moving today?
Latest CRDF news — Nov 12, 2026: Cardiff Oncology, Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Cardiff Oncology Posts Q3 2026 Results, Gives Business Update
What is the CRDF price target?
The average analyst price target for CRDF is $2.00, ranging from $2 to $2, based on 1 analysts.
What do analysts rate CRDF?
Analyst ratings for CRDF: 1 Buy, 0 Hold, 4 Sell — consensus Sell.
Did CRDF beat earnings?
CRDF last reported on Aug 11, 2026: EPS -$0.14 vs -$0.12 expected — a miss of 17.1%.
Does CRDF pay a dividend?
CRDF does not currently pay a dividend.
What are CRDF support and resistance levels?
Resistance: $0.75, $0.87, $0.95.
What are insiders doing with CRDF?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on CRDF?
Nov 12, 2026: Cardiff Oncology, Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Cardiff Oncology Posts Q3 2026 Results, Gives Business Update · Nov 12, 2026: Cardiff Oncology posts smaller quarterly loss than expected, revenue tops estimate